Targeting neutrophilic inflammation in obstructive airway disease - A narrative review of brensocatib therapy
- PMID: 40614835
- DOI: 10.1016/j.rmed.2025.108243
Targeting neutrophilic inflammation in obstructive airway disease - A narrative review of brensocatib therapy
Abstract
Brensocatib is an oral inhibitor of dipeptidyl peptidase 1, an enzyme that activates neutrophil serine proteases. Its potential to reduce neutrophil-driven inflammation has generated interest across a range of chronic inflammatory and respiratory conditions, particularly non-cystic fibrosis (CF) bronchiectasis. As the body of evidence supporting brensocatib continues to expand, there is a clear need for a comprehensive, rigorous, and practical narrative review to consolidate current knowledge and highlight gaps for future research. The aim of this narrative review was to systematically examine and synthesize the existing literature on brensocatib, including its pharmacology, therapeutic applications, clinical trial outcomes, safety profile, and ongoing research efforts. A systematic search was performed across major databases, EMBASE, MEDLINE, Scopus, Web of Science, Google Scholar, and ClinicalTrials.gov, through April 2025. Studies involving brensocatib in preclinical or clinical contexts were thoroughly reviewed to evaluate its efficacy and safety. Data were extracted on study design, population, dosage, outcomes, adverse events (AEs), and key findings. The most extensively studied indication was non-CF bronchiectasis, where brensocatib demonstrated a reduction in exacerbation rates and neutrophil protease activity. Preliminary evidence also suggests potential applications in CF, chronic obstructive pulmonary disease, and other neutrophilic conditions. An evaluation of the safety data indicates that the AEs reported are generally mild to moderate in severity. Brensocatib demonstrates potential as a novel anti-inflammatory therapy targeting neutrophil-mediated disease mechanisms. Further research is needed to evaluate its long-term efficacy, safety across a broader population, and its role in combination therapies.
Keywords: Brensocatib; Bronchiectasis; Dipeptidyl peptidase 1; Inflammation; Neutrophil elastase; Neutrophils.
Copyright © 2025 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest We have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Furthermore, we declare that this manuscript was not funded/sponsored, and no writing assistance was utilized in its production.
Similar articles
-
A profile of brensocatib for non-cystic fibrosis bronchiectasis.Expert Rev Respir Med. 2025 Aug;19(8):767-774. doi: 10.1080/17476348.2025.2508313. Epub 2025 May 22. Expert Rev Respir Med. 2025. PMID: 40387478 Review.
-
Dipeptidyl peptidase 1 inhibitors and neutrophilic inflammation in bronchiectasis: a narrative review.J Thorac Dis. 2025 Jul 31;17(7):5347-5360. doi: 10.21037/jtd-2025-289. Epub 2025 Jul 8. J Thorac Dis. 2025. PMID: 40809229 Free PMC article. Review.
-
Interventions for bronchiectasis: an overview of Cochrane systematic reviews.Cochrane Database Syst Rev. 2015 Jul 14;2015(7):CD010337. doi: 10.1002/14651858.CD010337.pub2. Cochrane Database Syst Rev. 2015. PMID: 26171905 Free PMC article.
-
Macrolide antibiotics (including azithromycin) for cystic fibrosis.Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD002203. doi: 10.1002/14651858.CD002203.pub5. Cochrane Database Syst Rev. 2024. PMID: 38411248 Free PMC article.
-
Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.Health Technol Assess. 2015 May;19(36):1-516. doi: 10.3310/hta19360. Health Technol Assess. 2015. PMID: 25980984 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous